FAQs

The 5th ALS Drug Development Summit is a three-day scientific conference (June 2–4, 2026) focused on accelerating therapies for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). It brings together leaders from biotech, pharma, academia, patient advocacy, and research funding to share insights on discovery, translational biology, clinical design, biomarkers, and regulatory strategy.

The program includes:

• 30 + world-class speakers with cutting-edge scientific and clinical content
• Two dedicated content tracks spanning discovery through clinical and regulatory strategy
• 10 + hours of face-to-face networking
• Pre-conference workshops and interactive sessions tackling mechanisms, models, trial design, and patient-centered endpoints

The Colonnade
120 Huntington Ave,
Boston, MA 02116
United States

Expect a group of 100 + senior experts across pharma, biotech, academia, clinical research, regulatory science, investment, and patient advocacy. Participating organizations include leading companies such as Biogen, Eli Lilly, Novartis, Takeda, QurAlis, Prilenia Therapeutics, Mitsubishi Tanabe Pharma, Sanofi, AbbVie, AskBio, uniQure, Trace Neuroscience, Everything ALS, and many others.

As a delegate, you will gain first-hand access to the latest advances in ALS and FTD drug development, spanning discovery biology through translational and clinical strategy. The summit provides an opportunity to hear directly from scientific and clinical leaders working on innovative therapeutic approaches, biomarkers, genetics, and disease modeling, while also offering practical insights into trial design and regulatory considerations. Beyond the scientific sessions, the event is designed to foster meaningful interaction with peers across biotech, pharma, academia, and patient organizations, enabling you to benchmark progress, exchange perspectives, and build collaborations that can accelerate the development of effective therapies for neurodegenerative disease.

You can register online today - here, and it only takes a few minutes. Select your chosen conference pass and submit your payment via our secure online portal. You'll receive a confirmation email containing your ticket details once your payment is confirmed.

If you need registration assistance, please contact our team at info@hansonwade.com

Sponsoring the 5th ALS Drug Development Summit provides a strategic platform to position your organization alongside the companies and researchers advancing next-generation ALS and FTD therapeutics. The meeting brings together decision-makers across discovery, translational research, and clinical development, giving sponsors the opportunity to showcase technologies, services, and solutions directly to highly relevant stakeholders. Through dedicated networking and brand visibility opportunities curated by Hanson Wade, sponsors can generate new business leads, gain competitive intelligence on evolving scientific challenges, and strengthen their presence within the rapidly advancing neurodegeneration research community.

Get in touch today sponsor@hansonwade.com

The summit runs June 2–4 2026 with workshops on June 2, followed by two days of dual‑track conference sessions, panels, and networking.

Yes — teams of two or more can secure discounted group rates.

Yes — reduced rates are available for academics, non‑profits, and patient groups. View registration options here.